Sensei Biotherapeutics Inc (SNSE) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access SNSE quarterly Cash Flow →
Tracking cash flow results across Sensei Biotherapeutics Inc to Dec 31 2021 helps illustrate how Dec 31 2025's cash generation has responded to changing business conditions.
Annual Report, GAAP in USD millions
ITEM
(Dec 31 2025)
12 Months
(Dec 31 2024) (Dec 31 2023) (Dec 31 2022) (Dec 31 2021)
Operating Activities
Income-21.09
Depreciation & amortization0.12
Amortization of Other Assets0.00
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Long-Lived Assets Held-for-use0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Assets, Total0.00
Share-based Compensation1.27
Income (Loss) from Equity Method Investments0.00
Fair Value of Assets Acquired0.00
Embedded Derivative Gain Loss On Embedded Derivative Net-
Finance Lease Interest Expense-
Interest On Capital Lease-
Operating Lease Right Of Use Asset Amortization Expense1.51
Finance Lease Right Of Use Asset Amortization0.02
Marketable Securities Realized Gain Loss-
Increase Decrease In Operating Lease Liabilities-1.59
Accretion On Marketable Securities-0.70
Finance Lease Impairment Loss-
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Employee Related Liabilities-0.56
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.23
Accrued Expense0.00
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense0.24
Other Working Capital0.08
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-20.45
Investing Activities
Capital Expenditures-0.02
Sale of Capital Items0.25
Short-term Investments Proceeds19.54
Short-term Investments Acq.0.00
Real Estate Investments0.00
Capital Proceeds Relating To Property And Equipment-
Insurance Proceeds Relating To Property And Equipment-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Payments to Acquire Businesses, Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities19.77
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.14
Proceeds From Exercise Of Common Stock Warrants And Options-
Finance Lease Principal Payments-0.79
Proceeds From Issuance Of Common Stock Upon Initial Public Offering Net Of Issuance Costs-
Capital Expenditures Incurred But Not Yet Paid-
Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction-
Noncash Interest On Financing-
Stock Issued-
Conversion Of Stock Amount Converted-
Employee Stock Purchase Plan Expense0.01
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities-0.65
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-20.22
Total Cash Flow-1.33
4 historic quarters locked

Sign in to unlock the full Sensei Biotherapeutics Inc cash flow history.

About Sensei Biotherapeutics Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-26-132014

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document





                    
Get the full CSIMarket dataset: Subscribe API License